Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study.

IF 1.7 Q3 PHARMACOLOGY & PHARMACY

Drug Research Pub Date : 2024-07-01 Epub Date: 2024-07-05 DOI:10.1055/a-2332-3253

Fatemah Abedipour, Hossein Hadavand Mirzaei, Hossein Ansari, Neda Ehsanzadeh, Amin Rashki, Mohammad Mahdi Vahedi, Asma Rashki

{"title":"Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study.","authors":"Fatemah Abedipour, Hossein Hadavand Mirzaei, Hossein Ansari, Neda Ehsanzadeh, Amin Rashki, Mohammad Mahdi Vahedi, Asma Rashki","doi":"10.1055/a-2332-3253","DOIUrl":null,"url":null,"abstract":"Background: There have been reports of serious side effects of Remdesivir, including cardiovascular complications. The present study aimed to determine the adverse cardiovascular effects of Remdesivir and the factors affecting them in COVID-19 patients.Methods: The patients were classified into two groups: those receiving Remdesivir without cardiac complications and those receiving Remdesivir with cardiovascular complications. After reviewing the patient's medical records, the relationship of some factors with the incidence of adverse cardiovascular effects was measured.Results: Chi-square test showed that the distribution of complications in men was significantly higher than in women (P=0.001). The independent t-test revealed that the mean age in the group with complications was significantly higher than the group without complications (P=0.013). Fisher's exact test demonstrated a significant relationship between smoking and cardiovascular complications (P=0.05). According to the Mann-Whitney test, a significant difference was found in the mean changes of Bilirubin (P=0.02) and ALKP (P=0.01) before and after treatment in the groups with and without heart complications.Conclusion: Our findings indicated that most of the COVID-19 patients suffered from sinus bradycardia, and the distribution of complications was more pronounced in men than in women. The mean age in the group with complications was higher than the group without complications. Smoking was found to be associated with the occurrence of cardiovascular complications and the mean changes of Bilirubin and ALKP before and after treatment were significantly different in the groups with and without cardiovascular complications.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"74 6","pages":"290-295"},"PeriodicalIF":1.7000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2332-3253","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There have been reports of serious side effects of Remdesivir, including cardiovascular complications. The present study aimed to determine the adverse cardiovascular effects of Remdesivir and the factors affecting them in COVID-19 patients.

Methods: The patients were classified into two groups: those receiving Remdesivir without cardiac complications and those receiving Remdesivir with cardiovascular complications. After reviewing the patient's medical records, the relationship of some factors with the incidence of adverse cardiovascular effects was measured.

Results: Chi-square test showed that the distribution of complications in men was significantly higher than in women (P=0.001). The independent t-test revealed that the mean age in the group with complications was significantly higher than the group without complications (P=0.013). Fisher's exact test demonstrated a significant relationship between smoking and cardiovascular complications (P=0.05). According to the Mann-Whitney test, a significant difference was found in the mean changes of Bilirubin (P=0.02) and ALKP (P=0.01) before and after treatment in the groups with and without heart complications.

Conclusion: Our findings indicated that most of the COVID-19 patients suffered from sinus bradycardia, and the distribution of complications was more pronounced in men than in women. The mean age in the group with complications was higher than the group without complications. Smoking was found to be associated with the occurrence of cardiovascular complications and the mean changes of Bilirubin and ALKP before and after treatment were significantly different in the groups with and without cardiovascular complications.

查看原文本刊更多论文

COVID-19患者与雷米替韦相关的心脏不良反应：病例对照研究

背景：有报道称雷米地韦具有严重的副作用，包括心血管并发症。本研究旨在确定雷米地韦对 COVID-19 患者心血管的不良反应及其影响因素：方法：将患者分为两组：接受雷米替韦治疗但未出现心脏并发症的患者和接受雷米替韦治疗但出现心血管并发症的患者。方法：将患者分为两组：接受雷米替韦治疗而无心脏并发症的患者和接受雷米替韦治疗而出现心血管并发症的患者，在查阅患者病历后，测定了一些因素与心血管不良反应发生率的关系：卡方检验显示，男性并发症的分布明显高于女性（P=0.001）。独立 t 检验显示，有并发症组的平均年龄明显高于无并发症组（P=0.013）。费雪精确检验表明，吸烟与心血管并发症之间存在显著关系（P=0.05）。根据 Mann-Whitney 检验，有心脏并发症组和无心脏并发症组治疗前后胆红素（P=0.02）和 ALKP（P=0.01）的平均变化有显著差异：我们的研究结果表明，大多数 COVID-19 患者患有窦性心动过缓，且并发症在男性中的分布比女性更明显。有并发症组的平均年龄高于无并发症组。研究发现，吸烟与心血管并发症的发生有关，有心血管并发症组和无心血管并发症组治疗前后胆红素和ALKP的平均变化有显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Research PHARMACOLOGY & PHARMACY-

CiteScore

3.50

自引率

0.00%

发文量

期刊介绍： Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.